PRMT5 inhibitors exerted promising effects on in vitro models of mesothelioma with MTAP deletion, as its inhibition selectively inhibited tumor cell proliferation and downregulated genes related to cell cycle and epithelial–mesenchymal transition [80]. The gene discussed is MTAP; the disease is mesothelioma.